195 related articles for article (PubMed ID: 27694157)
1. A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.
Chiappori AA; Otterson GA; Dowlati A; Traynor AM; Horn L; Owonikoko TK; Ross HJ; Hann CL; Abu Hejleh T; Nieva J; Zhao X; Schell M; Sullivan DM
Oncologist; 2016 Oct; 21(10):1163-1164. PubMed ID: 27694157
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
[TBL] [Abstract][Full Text] [Related]
4. Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis.
Imai H; Yamada Y; Minemura H; Sugiyama T; Kotake M; Kaira K; Kanazawa K; Nakamura Y; Kasai T; Shibata Y; Kaburagi T; Minato K;
Thorac Cancer; 2018 Dec; 9(12):1699-1706. PubMed ID: 30281216
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
Barata P; Cooney M; Tyler A; Wright J; Dreicer R; Garcia JA
Invest New Drugs; 2018 Jun; 36(3):451-457. PubMed ID: 29476383
[TBL] [Abstract][Full Text] [Related]
6. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
[TBL] [Abstract][Full Text] [Related]
8. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.
Fassnacht M; Berruti A; Baudin E; Demeure MJ; Gilbert J; Haak H; Kroiss M; Quinn DI; Hesseltine E; Ronchi CL; Terzolo M; Choueiri TK; Poondru S; Fleege T; Rorig R; Chen J; Stephens AW; Worden F; Hammer GD
Lancet Oncol; 2015 Apr; 16(4):426-35. PubMed ID: 25795408
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
von Pawel J; Jotte R; Spigel DR; O'Brien ME; Socinski MA; Mezger J; Steins M; Bosquée L; Bubis J; Nackaerts K; Trigo JM; Clingan P; Schütte W; Lorigan P; Reck M; Domine M; Shepherd FA; Li S; Renschler MF
J Clin Oncol; 2014 Dec; 32(35):4012-9. PubMed ID: 25385727
[TBL] [Abstract][Full Text] [Related]
10. A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.
Davis SL; Eckhardt SG; Diamond JR; Messersmith WA; Dasari A; Weekes CD; Lieu CH; Kane M; Choon Tan A; Pitts TM; Leong S
Oncologist; 2018 Dec; 23(12):1409-e140. PubMed ID: 30139840
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.
Heist RS; Fain J; Chinnasami B; Khan W; Molina JR; Sequist LV; Temel JS; Fidias P; Brainerd V; Leopold L; Lynch TJ
J Thorac Oncol; 2010 Oct; 5(10):1637-43. PubMed ID: 20808253
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
[TBL] [Abstract][Full Text] [Related]
13. Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy.
Evans TL; Cho BC; Udud K; Fischer JR; Shepherd FA; Martinez P; Ramlau R; Syrigos KN; Shen L; Chadjaa M; Wolf M
J Thorac Oncol; 2015 Aug; 10(8):1221-8. PubMed ID: 26200278
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial.
Kurata T; Kashii T; Takeda K; Seki N; Tsuboi M; Kobayashi M; Satoh T; Nakagawa K; Fukuoka M
J Thorac Oncol; 2009 May; 4(5):644-8. PubMed ID: 19325498
[TBL] [Abstract][Full Text] [Related]
15. Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
Takahashi N; Hao Z; Villaruz LC; Zhang J; Ruiz J; Petty WJ; Mamdani H; Riess JW; Nieva J; Pachecho JM; Fuld AD; Shum E; Chauhan A; Nichols S; Shimellis H; McGlone J; Sciuto L; Pinkiert D; Graham C; Shelat M; Kattappuram R; Abel M; Schroeder B; Upadhyay D; Krishnamurthy M; Sharma AK; Kumar R; Malin J; Schultz CW; Goyal S; Redon CE; Pommier Y; Aladjem MI; Gore SD; Steinberg SM; Vilimas R; Desai P; Thomas A
JAMA Oncol; 2023 Dec; 9(12):1669-1677. PubMed ID: 37824137
[TBL] [Abstract][Full Text] [Related]
16. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
17. Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
Ciuleanu TE; Ahmed S; Kim JH; Mezger J; Park K; Thomas M; Chen J; Poondru S; VanTornout JM; Whitcomb D; Blackhall F
Br J Cancer; 2017 Sep; 117(6):757-766. PubMed ID: 28772281
[TBL] [Abstract][Full Text] [Related]
18. Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease.
Enomoto Y; Inui N; Imokawa S; Karayama M; Hasegawa H; Ozawa Y; Matsui T; Yokomura K; Suda T
Cancer Chemother Pharmacol; 2015 Sep; 76(3):499-505. PubMed ID: 26134440
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C;
Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454
[TBL] [Abstract][Full Text] [Related]
20. A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer.
Kang JH; Lee KH; Kim DW; Kim SW; Kim HR; Kim JH; Choi JH; An HJ; Kim JS; Jang JS; Kim BS; Kim HT
Br J Cancer; 2021 Feb; 124(4):713-720. PubMed ID: 33191408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
